Reliable Testing is Crucialhttps://carestart.com/wp-content/uploads/2020/07/reliable-testing.jpg15481066CareStart™CareStart™https://carestart.com/wp-content/uploads/2020/07/reliable-testing.jpg
In March 2020, the World Health Organization declared COVID-19 (the disease caused by SARS-CoV-2 or the novel coronavirus) a pandemic. All of the leading global public health organizations agree that large-scale testing is essential to controlling the spread. Even after the development of a vaccine, we will still need to be able to test at high volumes to protect public health.
Because COVID-19 spread so rapidly in such a short time, many nations were not adequately prepared and were challenged to develop effective testing. In the United States, this shortage was exacerbated by a lack of oversite at the federal level: out of desperation to get tests out into the environment, the FDA allowed many unvetted, poor quality or defective tests to flood the market. It is unknown how many of these tests have been used, but it is likely that they have contributed to the difficulty in getting the pandemic under control in the United States.
Part of the answer lies with being able to access a variety of high-quality diagnostics tests that allow professionals to test not only for current exposure to the various but if the person being tested has been exposed to SARS-CoV-2 and has developed antibodies. To help meet this challenge, Intrivo has partnered with global in-vitro diagnostics leader Access Bio. With headquarters in New Jersey and a strong state-side supply chain, Access Bio has the capacity to produce more than 1.2 million tests a day.